- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04074798
Hyperventilation in Patients With Chronic Low Back Pain (HELBP)
August 21, 2024 updated by: Lotte Janssens, Hasselt University
Low back pain (LBP) is the leading cause of disability worldwide.
Impaired postural control is a key factor in the development and maintenance of LBP.
Moreover, the prevalence of LBP is associated with impairments in diaphragm function, symptoms of dyspnea, and dysfunctional breathing.
However, the association between LBP (and more specifically postural control) and hyperventilation remains unknown.
The main objective of this project is to investigate whether the presence of recurrent non-specific LBP is related to the presence of hyperventilation, when classified either objectively by decreased carbon dioxide values (demonstrating hypocapnia) or by symptoms while showing normal carbon dioxide values.
Moreover, the investigators will explore whether psychosocial factors play a role in this relation.
Subsequently, the investigators will examine whether hyperventilation in LBP patients is related to impaired postural control, and more specifically to a decreased postural contribution of the diaphragm.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
90
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Katleen Bogaerts, PhD, PT
- Email: Katleen.Bogaerts@uhasselt.be
Study Contact Backup
- Name: Sofie Van Wesemael, MSc, PT
- Phone Number: +32472771468
- Email: sofie.vanwesemael@uhasselt.be
Study Locations
-
-
-
Hasselt, Belgium, 3590
- Recruiting
- Hasselt University
-
Contact:
- Lotte Janssens, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria Patients:
- Chronic primary low back pain (>12 weeks) as diagnosed by a medical doctor
Inclusion Criteria Healthy controls:
- No low back pain
Exclusion Criteria:
- Insufficient understanding of Dutch language
- Previous spinal surgery
- Chronic Obstructive Lung Disease, Interstitial Lung Disease, pulmonary vascular disease, asthma except for exertional asthma
- Acute cardiovascular or gastrointestinal disorders
- Neuromuscular disease interfering with normal lower limb or trunk functioning
- Acute pain or secondary chronic pain
- Pregnant and lactating women
- Major psychiatric conditions
- Acute lower limb problems
- Vestibular disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: Healthy controls
|
assessment of hyperventilation, postural control and psychological behavior
|
|
Active Comparator: Patients with low back pain
|
assessment of hyperventilation, postural control and psychological behavior
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nijmegen questionnaire
Time Frame: Day 1
|
Questionnaire evaluating hyperventilation symptoms, 16 items, total score range 0-64
|
Day 1
|
|
Nijmegen questionnaire
Time Frame: Day 4
|
Questionnaire evaluating hyperventilation symptoms, 16 items, total score range 0-64
|
Day 4
|
|
PetCO2
Time Frame: Day 1
|
End-tidal carbon dioxide pressure measured with a capnograph
|
Day 1
|
|
Postural control
Time Frame: Day 1
|
upright standing balance measured by center of pressure by force plate
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Breathing frequency
Time Frame: Day 1
|
amount of breaths per minute, inspiratory and expiratory time
|
Day 1
|
|
Breathing pattern (abominal and thoracic)
Time Frame: Day 1
|
abdominal or thoracic contribution to one breath measured by respiratory inductance plethysmography
|
Day 1
|
|
Numerical Rating Scale for low back pain (NRS)
Time Frame: Day 1
|
11 point Likert scale evaluating severity/intensity of back pain, ranging from 0 (no pain) to 11 (worst pain imaginable)
|
Day 1
|
|
Oswestry Disability Index version 2.1a (ODI-2.1a)
Time Frame: Day 1
|
Questionnaire evaluating disability.
10 items Total score range from 0-100
|
Day 1
|
|
12-item Short form Health Survey (SF-12)
Time Frame: Day 1
|
Questionnaire evaluating physical and mental components of health related quality of life.
12 items.
Total score range 12-56.
|
Day 1
|
|
Fear Avoidance Component Scale (FACS)
Time Frame: Day 1
|
Questionnaire evaluating fear-avoidance related to pain.
20 items Total score range from 0-100
|
Day 1
|
|
Tampa Scale for Kinesiophobia (TSK)
Time Frame: Day 1
|
Questionnaire evaluating kinesiophobia related to pain.
17 items.
Total score range from 17-68
|
Day 1
|
|
Pain Catastrophizing Scale (PCS)
Time Frame: Day 1
|
Questionnaire evaluating catastrophizing.
13 items, 5 point Likert scale.
Total score 0-52
|
Day 1
|
|
Need for Controllability and Predictability Questionnaire (NCP-Q)
Time Frame: Day 1
|
Questionnaire evaluating the need for being able to control and predict situations.
15 items, 5 point Likert scale.
Total score range 15 - 75
|
Day 1
|
|
Positive And Negative Affect Schedule (PANAS)
Time Frame: Day 1
|
Questionnaire evaluating positive and negative affect.
10 items positive affect, 10 items negative affect, 5 point Likert scale.
Total score range per affect: 10 - 50
|
Day 1
|
|
Pain Solutions Questionnaire (PaSoL)
Time Frame: Day 1
|
Questionnaire evaluating assimilative and accommodative responses to problems associated with pain.
14 items, 7 point Likert scale.
Total score range 0 - 84
|
Day 1
|
|
Toronto Alexithymia Scale 20 (TAS-20)
Time Frame: Day 1
|
Questionnaire evaluating characteristics linked to alexithymia.
20 items, 3 factors.
Total score range 20 - 100
|
Day 1
|
|
Interoceptive Awareness Questionnaire (IAQ)
Time Frame: Day 1
|
Questionnaire evaluating adaptive and maladaptive body awareness.
19 items, 5 point Likert scale.
|
Day 1
|
|
Fremantle Back Awareness Questionnaire (FreBAQ)
Time Frame: Day 1
|
Questionnaire evaluating back specific perceptual awareness.
9 items, 5 point Likert scale.
Total score range 0-36
|
Day 1
|
|
Vragenlijst belastende ervaringen (VBE) - short version
Time Frame: Day 1
|
Questionnaire evaluating aversive experiences in adult life.
11 items should be scored with yes or no.
If yes a score on a 5 point Likert scale should be given.
|
Day 1
|
|
Multidimensional Perfectionism Scale (MPS)
Time Frame: Day 1
|
Questionnaire evaluating adaptive and maladaptive perfectionism.
35 items, 5 point Likert scale.
Total score range 35 - 175
|
Day 1
|
|
International Physical Activity Questionnaire - Short Form (IPAQ-SF)
Time Frame: Day 1
|
Questionnaire evaluating subjective level of physical activity.
7 questions regarding amount of time spent on certain activities.
|
Day 1
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate
Time Frame: Day 1
|
ECG measurement to determine heart rate variability
|
Day 1
|
|
Skin conductance
Time Frame: Day 1
|
The resistance / conductance of the skin, stress physiological measure
|
Day 1
|
|
Activity of abdominal muscles
Time Frame: Day 1
|
The amount of muscle activation measured by electromyography
|
Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Lotte Janssens, PhD, PT, Hasselt University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2020
Primary Completion (Estimated)
July 1, 2025
Study Completion (Estimated)
July 1, 2025
Study Registration Dates
First Submitted
August 28, 2019
First Submitted That Met QC Criteria
August 28, 2019
First Posted (Actual)
August 30, 2019
Study Record Updates
Last Update Posted (Actual)
August 22, 2024
Last Update Submitted That Met QC Criteria
August 21, 2024
Last Verified
August 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CME ZOL - CTU2019078
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Back Pain, Recurrent
-
University of Kansas Medical CenterCompletedLower Back Pain | Low Back Pain | Low Back Pain, Mechanical | Low Back Pain, Recurrent | Low Back Pain, Postural | Postural Low Back Pain | Mechanical Low Back Pain | Low Back Ache | Recurrent Low Back Pain | Lower Back Pain Chronic | Low Back Pain, Posterior Compartment | Low BackacheUnited States
-
Karolinska InstitutetCompletedChronic Low Back Pain | Recurrent Low Back Pain | Persistent Low Back PainSweden
-
Istanbul UniversityIstinye UniversityCompletedLow Back Pain | Low Back Pain, Mechanical | Low Back Pain, Recurrent | Low Back Pain, PosturalTurkey
-
University GhentFund for Scientific Research, Flanders, BelgiumRecruiting
-
Universität Duisburg-EssenSiemens-BetriebskrankenkasseCompletedChronic Low Back Pain | Recurrent Low Back Pain
-
Universidade Federal do PiauíFoundation for Research Support of the State of PiauíCompletedLow Back Pain, Recurrent | Chronic Low Back PainBrazil
-
MMJ Labs LLCNational Institute on Drug Abuse (NIDA); Sport and Spine Rehab Clinical Research...CompletedLow Back Pain | Low Back Pain, Recurrent | Low Back SprainUnited States
-
National Taiwan University HospitalNational Health Research Institutes, TaiwanCompletedRecurrent Low Back PainTaiwan
-
Studio Osteopatico Busto ArsizioCompleted
-
University of Applied Health SciencesCompletedChronic Low-back Pain | Low Back Pain, Recurrent | LumbagoCroatia
Clinical Trials on assessment of hyperventilation, postural control and psychological behavior
-
Hasselt UniversityKU LeuvenRecruitingLow Back Pain | Pelvic Girdle Pain | Lumbopelvic PainBelgium
-
Hasan Kalyoncu UniversityRecruiting
-
Hasselt UniversityZiekenhuis Oost-LimburgRecruitingLow Back Pain | Pelvic Girdle PainBelgium
-
National Center for AIDS/STD Control and Prevention...UnknownUsing HIV Risk Assessment Tool to Promote HIV Testing Among Men Who Have Sex With Men (online-RASSL)HIV Infections | HIV/AIDS | Social MediaChina
-
The New SchoolUniversity of ZurichCompletedSelf EfficacyUnited States
-
Centre Hospitalier Universitaire de NiceCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Head and Neck NeoplasmUnited States
-
Jianersheng (Zhuhai) Pharmaceutical Technology...Completed
-
Hasselt UniversityJessa HospitalCompletedHip Pain Chronic | Musculoskeletal Pain | Neck Pain | Low Back Pain, Recurrent | Shoulder Pain | PROMs | Fear of Pain | Musculoskeletal Pain Disorder | Knee Pain Chronic | Fear of InjuryBelgium
-
M.D. Anderson Cancer CenterActive, not recruitingClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditionsUnited States